Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION [SIN15468P]

NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION [SIN15468P]

Active ingredients: NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION

Last updated 26 October 2025

On this page

Product Info
4.3 Contraindications

Product Info

NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION

[SIN15468P]

Product information

Active Ingredient and Strength

ALANINE - 4.656 G/1,000 ML
ARGININE - 2.592 G/1,000 ML
ASPARTIC ACID - 1.44 G/1,000 ML
CALCIUM CHLORIDE DIHYDRATE - 0.47 G/1,000 ML
GLUCOSE MONOHYDRATE EQV TO ANHYDROUS GLUCOSE 120 G/1,000 ML - 132 G/1,000 ML
GLUTAMIC ACID - 3.368 G/1,000 ML
GLYCINE - 1.584 G/1,000 ML
HISTIDINE HYDROCHLORIDE MONOHYDRATE EQV TO HISTIDINE 1.2 G/1,000 ML - 1.624 G/1,000 ML
ISOLEUCINE - 2.256 G/1,000 ML
LEUCINE - 3.008 G/1,000 ML
LYSINE HYDROCHLORIDE EQV TO LYSINE 2.184 G/1,000 ML - 2.728 G/1,000 ML
MAGNESIUM ACETATE TETRAHYDRATE - 0.686 G/1,000 ML
METHIONINE - 1.88 G/1,000 ML
OMEGA-3-ACID TRIGLYCERIDES - 4 G/1,000 ML
PHENYLALANINE - 3.368 G/1,000 ML
POTASSIUM ACETATE - 2.747 G/1,000 ML
PROLINE - 3.264 G/1,000 ML
SERINE - 2.88 G/1,000 ML
SODIUM ACETATE TRIHYDRATE - 0.222 G/1,000 ML
SODIUM CHLORIDE - 0.402 G/1,000 ML
SODIUM DIHYDROGEN PHOSPHATE DIHYDRATE - 1.872 G/1,000 ML
SODIUM HYDROXIDE - 0.781 G/1,000 ML
SOYA-BEAN OIL, REFINED - 16 G/1,000 ML
THREONINE - 1.744 G/1,000 ML
TRIGLYCERIDES, MEDIUM CHAIN - 20 G/1,000 ML
TRYPTOPHAN - 0.544 G/1,000 ML
VALINE - 2.496 G/1,000 ML
ZINC ACETATE DIHYDRATE - 5.264 MG/1,000 ML

Dosage Form

INJECTION, EMULSION

Manufacturer and Country

B. BRAUN MELSUNGEN AG - GERMANY

Registration Number

SIN15468P

Licence Holder

B. BRAUN SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

B05BA10

4.1 Therapeutic indications
Supply of energy, essential fatty acids including omega-3 and omega-6 fatty acids, amino acids, electrolytes and fluids for parenteral nutrition of patients in states of moderate to severe catabolism when oral or enteral nutrition is impossible, insufficient or contraindicated. Nutriflex Omega plus is indicated in adults.

4.2 Posology and method of administration
Posology
The dosage should be adapted to the patients’ individual requirements. It is recommended that Nutriflex Omega plus be administered continuously. A stepwise increase of the infusion rate over the first 30 minutes up to the desired infusion rate avoids possible complications.

Adults
The maximum daily dose amounts to 40 ml/ kg body weight, corresponding to

Table caption

1.54 g amino acids

/ kg body weight per day

4.8 g glucose

/ kg body weight per day

1.6 g lipid

/ kg body weight per day.

The maximum rate of infusion is 2.0 ml/ kg body weight per hour, corresponding to

Table caption

0.08 g amino acids

/ kg body weight per hour

0.24 g glucose

/ kg body weight per hour

0.08 g lipid

/ kg body weight per hour.

For a patient weighing 70 kg, this corresponds to a maximum infusion rate of 140 ml per hour. The amount of substrate administered is then 5.4 g of amino acids per hour, 16.8 g of glucose per hour and 5.6 g of lipids per hour.

Paediatric population
Nutriflex Omega plus is contraindicated in newborn infants, infants and toddlers < 2 years of age (see section 4.3). Safety and efficacy in children > 2 years and adolescents have not been established.

Patients with renal/hepatic impairment
The doses should be adjusted individually in patients with hepatic or renal insufficiency (see also section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Duration of treatment
The duration of treatment for the indications stated is not limited. During the administration of Nutriflex Omega plus it is necessary to provide an appropriate amount of trace elements and vitamins.

Duration of infusion of one single bag
The recommended duration of infusion for a parenteral nutrition bag is maximum 24 h.

Method of administration
Intravenous use. For central venous infusion only.

4.3 Contraindications

  • Hypersensitivity to the active substances, to egg, fish, peanut or soya protein or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information

  • Inborn errors of amino acid metabolism

  • Severe hypertriglyceridaemia (≥ 1000 mg/dl or 11.4 mmol/l)

  • Severe coagulopathy

  • Hyperglycaemia not responding to insulin doses of up to 6 units insulin/hour

  • Acidosis

  • Intrahepatic cholestasis

  • Severe hepatic insufficiency

  • Severe renal insufficiency in absence of renal replacement therapy

  • Aggravating haemorrhagic diatheses

  • Acute thrombo-embolic events, lipid embolism

On account of its composition, Nutriflex Omega plus must not be used in newborn infants, infants and toddlers under 2 years of age.

General contraindications to parenteral nutrition include:

  • Unstable circulatory status with vital threat (states of collapse and shock)

  • Acute phases of cardiac infarction and stroke

  • Unstable metabolic condition (e.g. severe postaggression syndrome, coma of unknown origin)

  • Inadequate cellular oxygen supply

  • Disturbances of the electrolyte and fluid balance

  • Acute pulmonary oedema

  • Decompensated cardiac insufficiency